Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM82Y75)

• Drug Name: PIRINIXIC ACID Drug Info
• Synonyms: Pirinixic acid; 50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-(

Indication

Disease Entry	ICD 11	Status	REF
Pulmonary fibrosis	CB03.4	Preclinical	[1]

• Cross-matching ID:
  PubChem CID: 5694
  ChEBI ID: CHEBI:32509
  CAS Number: CAS 50892-23-4
  TTD Drug ID: DM82Y75

Molecule-Related Drug Atlas

Drug(s) Targeting Peroxisome proliferator-activated receptor alpha (PPARA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lobeglitazone	DMHY3IP	Type-2 diabetes	5A11	Approved	[11]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[12]
Bezafibrate	DMZDCS0	Hypercholesterolaemia	5C80.0	Approved	[13]
Ciprofibrate	DMGC5DB	Hyperlipoproteinemia	5C80	Approved	[12]
Pemafibrate	DMD1VZL	Hyperlipidemia	5C80.Z	Approved	[14]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[15]
Ragaglitazar	DMFSHEM	Type-1 diabetes	5A10	Phase 3	[16]
CS-038	DM67P0F	Type-2 diabetes	5A11	Phase 3	[17]
TESAGLITAZAR	DMGRBN5	Type-1 diabetes	5A10	Phase 3	[18]
GFT-505	DM7ZOAE	Non-alcoholic steatohepatitis	DB92.1	Phase 3	[19]

Drug(s) Affected By Liver carboxylesterase 1 (CES1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[20]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[21]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[22]
Selenium	DM25CGV	N. A.	N. A.	Approved	[23]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[26]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[27]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[29]

Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[30]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[31]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[32]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[34]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[35]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[36]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[37]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[38]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]

Drug(s) Affected By Peroxisome proliferator-activated receptor gamma (PPARG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[40]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[41]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[43]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[44]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[45]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[46]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[47]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[48]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[49]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[50]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[51]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[52]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[55]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[56]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[57]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[58]

Drug(s) Affected By Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[37]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[60]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[61]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[62]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[63]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[65]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[66]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[67]

Drug(s) Affected By Aldo-keto reductase family 1 member B1 (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[72]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[75]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[72]

Drug(s) Affected By Polyunsaturated fatty acid 5-lipoxygenase (ALOX5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[76]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[77]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[78]
Fructose	DM43AN2	Vomiting	MD90	Approved	[79]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[82]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[75]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[83]

Drug(s) Affected By Prostaglandin E synthase 2 (PTGES2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[84]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[86]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[87]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[88]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[89]

Drug(s) Affected By Prostaglandin E synthase (PTGES)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[90]
Selenium	DM25CGV	N. A.	N. A.	Approved	[23]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[91]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[47]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[93]
Mestranol	DMG3F94	Contraception	QA21	Approved	[90]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[94]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[95]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[10]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[96]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[96]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[97]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[10]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[96]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[98]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[10]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[99]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[10]

Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[101]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[102]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[103]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[104]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[28]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[72]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[106]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[107]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[108]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[109]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[110]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[110]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[82]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[111]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[112]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[113]

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[114]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[115]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[116]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[117]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[118]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[119]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[120]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[121]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[122]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[123]

Drug(s) Affected By Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[124]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[126]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[127]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[128]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]

Drug(s) Affected By Synaptophysin (SYP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[131]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[132]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[133]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[132]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[134]
Methamphetamine	DMPM4SK	Anxiety		Approved	[135]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[136]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[137]

Drug(s) Affected By Drebrin (DBN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[127]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[138]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[133]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[95]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[84]

Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[139]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[140]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[139]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[140]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[141]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[139]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[139]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[139]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[142]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[143]

Drug(s) Affected By Bifunctional epoxide hydrolase 2 (EPHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Selenium	DM25CGV	N. A.	N. A.	Approved	[23]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[145]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[128]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[9]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[9]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[75]

Drug(s) Affected By Cytochrome P450 2J2 (CYP2J2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[146]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[147]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[148]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[149]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[146]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[146]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[150]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[9]

Drug(s) Affected By POTE ankyrin domain family member B (POTEB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[151]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[151]

Drug(s) Affected By POTE ankyrin domain family member C (POTEC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[151]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[151]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[88]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[89]

Drug(s) Affected By Nephrin (NPHS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[152]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[154]
Bezafibrate	DMZDCS0	Hypercholesterolaemia	5C80.0	Approved	[155]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[156]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[157]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[88]
Puromycin	DMDKLB5	N. A.	N. A.	Preclinical	[158]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[159]

Drug(s) Affected By Low-density lipoprotein receptor (LDLR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[160]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[160]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[162]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[163]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[102]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[127]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[165]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[166]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[167]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[38]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[168]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[38]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[169]
Selenium	DM25CGV	N. A.	N. A.	Approved	[170]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[171]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[172]

Drug(s) Affected By Apolipoprotein A-I (APOA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[173]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[175]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[67]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[176]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[177]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[178]

Drug(s) Affected By Catalase (CAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[168]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[179]
Haloperidol	DM96SE0	Delirium		Approved	[180]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[181]
Selenium	DM25CGV	N. A.	N. A.	Approved	[182]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[183]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[184]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]

Drug(s) Affected By Plasminogen activator inhibitor 1 (SERPINE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[188]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[191]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[192]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[193]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[194]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[145]

Drug(s) Affected By Fatty acid-binding protein, liver (FABP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[195]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[196]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[195]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[195]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[195]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[197]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[198]

Drug(s) Affected By Choriogonadotropin subunit beta 3 (CGB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[199]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[200]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[201]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[202]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[203]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[202]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[136]
Bezafibrate	DMZDCS0	Hypercholesterolaemia	5C80.0	Approved	[204]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[205]

Drug(s) Affected By Retinoic acid receptor RXR-alpha (RXRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[206]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Selenium	DM25CGV	N. A.	N. A.	Approved	[207]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[208]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[209]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[210]
Acitretin	DM8BKU9	Psoriasis vulgaris	EA90	Approved	[211]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[212]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[213]

Drug(s) Affected By Tumor necrosis factor alpha-induced protein 3 (TNFAIP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[214]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[215]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[216]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[217]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[214]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[218]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[219]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[214]

Drug(s) Affected By Cytochrome P450 7A1 (CYP7A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[220]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[101]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[221]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[222]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[223]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[224]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[194]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[122]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[222]

Drug(s) Affected By C-X-C motif chemokine 5 (CXCL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[225]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[188]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[226]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[227]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[228]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[229]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[230]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[231]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[75]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[232]

Drug(s) Affected By Solute carrier family 15 member 1 (SLC15A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[127]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[233]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[234]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[235]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[236]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[237]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[238]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[75]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[237]

Drug(s) Affected By Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[239]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[240]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[65]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[127]
Haloperidol	DM96SE0	Delirium		Approved	[239]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[241]

Drug(s) Affected By Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[242]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[197]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[227]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[243]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[244]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[245]

Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[246]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[102]
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[247]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[144]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[137]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[129]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[248]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[249]

Drug(s) Affected By GTP-binding protein RAD (RRAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[28]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[81]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[250]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[251]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[252]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[95]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[253]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]

Drug(s) Affected By Tumor protein D52 (TPD52)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[214]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[65]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[214]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[254]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[214]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[255]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[256]

Drug(s) Affected By Cytochrome P450 4A11 (CYP4A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[257]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[258]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[258]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[259]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[259]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[258]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[258]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[258]

Drug(s) Affected By Peroxisome proliferator-activated receptor delta (PPARD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[260]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[261]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[65]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[262]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[28]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[263]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[264]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]

Drug(s) Affected By Glycine N-methyltransferase (GNMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[102]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[151]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[151]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[128]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[265]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[102]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[256]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[266]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[267]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[197]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[268]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[194]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[66]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[270]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]

Drug(s) Affected By Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[125]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[228]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[241]
Ciprofibrate	DMGC5DB	Hyperlipoproteinemia	5C80	Approved	[272]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[273]
Sodium Acetate Anhydrous	DMH21E0	Hyponatraemia	5C72	Approved	[274]

Drug(s) Affected By kinase isozyme 4, mitochondrial (PDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[275]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[276]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[277]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[244]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[212]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[212]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[212]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[250]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[229]

Drug(s) Affected By Programmed cell death protein 4 (PDCD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[214]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[278]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[214]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[279]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[254]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[280]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[28]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[214]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[228]

Drug(s) Affected By POTE ankyrin domain family member D (POTED)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[281]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[88]
2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE	DMNQL17	Discovery agent	N.A.	Investigative	[282]

Drug(s) Affected By Cytochrome P450 4X1 (CYP4X1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[283]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[284]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[102]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[137]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[129]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[249]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[238]

Drug(s) Affected By Thyroid hormone-inducible hepatic protein (THRSP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[102]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[285]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[102]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[102]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[119]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]
Mitotane	DMU1GX0	Adrenocortical carcinoma	2D11.Z	Approved	[119]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[286]

Drug(s) Affected By Bcl-2-modifying factor (BMF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[287]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[288]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[289]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[128]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[212]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[290]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[102]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[93]

Drug(s) Affected By Nectin-4 (NECTIN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[291]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[255]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[251]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[265]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[136]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[86]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[292]

Drug(s) Affected By Perilipin-2 (PLIN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[293]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[102]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[294]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[127]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[254]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[212]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[128]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[295]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]

Drug(s) Affected By Ankyrin repeat domain-containing protein 30A (ANKRD30A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[296]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[88]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[296]

Drug(s) Affected By Angiopoietin-related protein 4 (ANGPTL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[180]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[217]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[212]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[128]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[212]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[212]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]

Drug(s) Affected By Leucine-rich melanocyte differentiation-associated protein (LRMDA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[73]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[265]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[297]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[86]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[137]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[298]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[299]

Drug(s) Affected By Ankyrin repeat domain-containing protein 26 (ANKRD26)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[300]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[74]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[85]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[292]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[301]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[298]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[238]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[88]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor alpha (PPARA)	TTJ584C	PPARA_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member B1 (AKR1B1)	OTRX72TH	ALDR_HUMAN	Gene/Protein Processing	[3]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Gene/Protein Processing	[4]
Angiopoietin-related protein 4 (ANGPTL4)	OTQL5SPX	ANGL4_HUMAN	Gene/Protein Processing	[5]
Ankyrin repeat domain-containing protein 26 (ANKRD26)	OT2ENKKV	ANR26_HUMAN	Gene/Protein Processing	[6]
Ankyrin repeat domain-containing protein 30A (ANKRD30A)	OTJXYAE5	AN30A_HUMAN	Gene/Protein Processing	[6]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Gene/Protein Processing	[7]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[8]
Bcl-2-modifying factor (BMF)	OT90NSLI	BMF_HUMAN	Gene/Protein Processing	[5]
Bifunctional epoxide hydrolase 2 (EPHX2)	OTPTRCNW	HYES_HUMAN	Gene/Protein Processing	[9]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[10]

References

• [1] Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
• [2] O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90.
• [3] WY 14,643 inhibits human aldose reductase activity. J Enzyme Inhib Med Chem. 2006 Oct;21(5):569-73.
• [4] Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
• [5] PPAR-mediated responses in human adult liver stem cells: In vivo/in vitro and cross-species comparisons. J Steroid Biochem Mol Biol. 2013 Nov;138:236-47. doi: 10.1016/j.jsbmb.2013.06.004. Epub 2013 Jun 27.
• [6] Immunoselection and characterization of a human genomic PPAR binding fragment located within POTE genes. Biochimie. 2007 Mar;89(3):329-36. doi: 10.1016/j.biochi.2006.09.017. Epub 2006 Oct 18.
• [7] Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994 Dec 9;269(49):31012-8.
• [8] PPARalpha activation potentiates AhR-induced CYP1A1 expression. Toxicology. 2005 Dec 15;216(2-3):122-8.
• [9] Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
• [10] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [11] Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
• [12] Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
• [13] Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
• [14] Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
• [15] Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
• [16] Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
• [17] Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
• [18] Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
• [19] Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
• [20] Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
• [21] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [22] Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999 Jul;290(1):314-8.
• [23] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [24] Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans. 2003 Jun;31(Pt 3):620-4. doi: 10.1042/bst0310620.
• [25] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [26] Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol. 2003 Apr;10(4):341-9. doi: 10.1016/s1074-5521(03)00071-1.
• [27] Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
• [28] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [29] Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
• [30] Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
• [31] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [32] Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
• [33] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [34] Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
• [35] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [36] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [37] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [38] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [39] A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
• [40] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [41] The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
• [42] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
• [43] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [44] Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
• [45] Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
• [46] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [47] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [48] Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
• [49] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [50] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [51] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [52] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [53] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [54] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [55] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [56] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [57] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [58] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [59] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [60] Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
• [61] Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
• [62] Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
• [63] Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
• [64] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [65] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [66] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [67] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [68] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [69] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [70] Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. Chem Biol Interact. 2009 Mar 16;178(1-3):250-8. doi: 10.1016/j.cbi.2008.11.007. Epub 2008 Nov 18.
• [71] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [72] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [73] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [74] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [75] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [76] Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38.
• [77] Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34.
• [78] Molecular actions of ebselen--an antiinflammatory antioxidant. Gen Pharmacol. 1995 Oct;26(6):1153-69.
• [79] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [80] Immediate up-regulation of the calcium-binding protein S100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim Biophys Acta. 2005 Sep 10;1745(2):156-65.
• [81] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [82] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [83] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [84] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [85] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [86] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [87] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [88] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [89] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
• [90] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [91] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [92] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [93] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [94] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [95] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [96] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [97] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [98] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [99] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [100] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [101] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [102] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [103] Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
• [104] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [105] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [106] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [107] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [108] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [109] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [110] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [111] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [112] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [113] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [114] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [115] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [116] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [117] Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
• [118] Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
• [119] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [120] Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
• [121] Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
• [122] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [123] Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
• [124] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [125] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [126] Activation of the constitutive androstane receptor by monophthalates. Chem Res Toxicol. 2016 Oct 17;29(10):1651-1661.
• [127] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [128] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [129] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [130] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [131] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [132] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [133] The induction of cytochrome P450 2E1 by ethanol leads to the loss of synaptic proteins via PPARalpha down-regulation. Toxicology. 2017 Jun 15;385:18-27.
• [134] The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Int J Cancer. 2009 Jul 1;125(1):235-43. doi: 10.1002/ijc.24331.
• [135] Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):467-74. doi: 10.1097/00126334-200312150-00004.
• [136] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [137] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [138] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [139] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [140] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [141] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [142] Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
• [143] Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
• [144] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [145] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [146] Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
• [147] In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica. 2003 Jun;33(6):615-23.
• [148] Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006 Dec;319(3):1162-71.
• [149] Cytochrome P450 expression, induction and activity in human induced pluripotent stem cell-derived intestinal organoids and comparison with primary human intestinal epithelial cells and Caco-2 cells. Arch Toxicol. 2021 Mar;95(3):907-922. doi: 10.1007/s00204-020-02953-6. Epub 2020 Dec 2.
• [150] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [151] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [152] Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int. 2006 Jul;70(1):177-86. doi: 10.1038/sj.ki.5001515. Epub 2006 May 17.
• [153] Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. Br J Pharmacol. 2018 Dec;175(23):4371-4385. doi: 10.1111/bph.14495. Epub 2018 Nov 6.
• [154] Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol. 2006 Jun;17(6):1624-32. doi: 10.1681/ASN.2005090983. Epub 2006 May 10.
• [155] PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1818-24. doi: 10.1016/j.bbrc.2005.10.158. Epub 2005 Nov 2.
• [156] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [157] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [158] Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol. 2001 May;158(5):1723-31. doi: 10.1016/S0002-9440(10)64128-4.
• [159] Bisphenol A Exposure Changes the Transcriptomic and Proteomic Dynamics of Human Retinoblastoma Y79 Cells. Genes (Basel). 2021 Feb 11;12(2):264. doi: 10.3390/genes12020264.
• [160] Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue. Contraception. 2007 Oct;76(4):297-305. doi: 10.1016/j.contraception.2007.06.011. Epub 2007 Sep 14.
• [161] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [162] Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. J Biol Chem. 2020 Nov 20;295(47):15870-15882. doi: 10.1074/jbc.RA120.015623. Epub 2020 Sep 10.
• [163] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [164] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [165] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [166] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [167] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [168] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [169] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [170] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [171] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [172] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [173] Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
• [174] Quercetin represses apolipoprotein B expression by inhibiting the transcriptional activity of C/EBP. PLoS One. 2015 Apr 15;10(4):e0121784. doi: 10.1371/journal.pone.0121784. eCollection 2015.
• [175] Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. Metabolism. 2004 Jun;53(6):766-71. doi: 10.1016/j.metabol.2003.11.027.
• [176] Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1336-41. doi: 10.1161/ATVBAHA.109.192088. Epub 2009 Aug 10.
• [177] The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990 Jul;120(1):172-9. doi: 10.1016/0002-8703(90)90175-w.
• [178] Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol. 2002 Apr-Jun;1(2):85-9.
• [179] Role of antioxidant systems in human androgen-independent prostate cancer cells. Prostate. 2000 May 1;43(2):144-9. doi: 10.1002/(sici)1097-0045(20000501)43:2<144::aid-pros9>3.0.co;2-h.
• [180] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [181] Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83. Int J Mol Sci. 2020 Aug 1;21(15):5533. doi: 10.3390/ijms21155533.
• [182] Selenium deficiency alters epithelial cell morphology and responses to influenza. Free Radic Biol Med. 2007 Jun 15;42(12):1826-37.
• [183] Hepatocellular peroxisomes in human alcoholic and drug-induced hepatitis: a quantitative study. Hepatology. 1991 Nov;14(5):811-7.
• [184] Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci. 2004 Aug;254(4):231-5.
• [185] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [186] The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
• [187] Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res. 2010 Oct;27(10):2162-74. doi: 10.1007/s11095-010-0219-2. Epub 2010 Jul 29.
• [188] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [189] Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
• [190] Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
• [191] Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
• [192] Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 2007;121(1):59-65. doi: 10.1016/j.thromres.2007.02.001. Epub 2007 Mar 26.
• [193] Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000 Mar;43(3):377-83. doi: 10.1007/s001250050057.
• [194] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [195] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [196] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [197] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [198] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [199] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [200] The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
• [201] Pharmacological doses of testosterone upregulated androgen receptor and 3-Beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase and impaired leydig cells steroidogenesis in adult rats. Toxicol Sci. 2011 Jun;121(2):397-407. doi: 10.1093/toxsci/kfr063. Epub 2011 Apr 6.
• [202] Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol. 2005 Oct;19(10):2502-16.
• [203] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [204] Expression of cFABP and PPAR in trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation. Biochim Biophys Acta. 2005 Feb 21;1687(1-3):181-94. doi: 10.1016/j.bbalip.2004.11.017.
• [205] The inhibitory effects of manganese on steroidogenesis in rat primary Leydig cells by disrupting steroidogenic acute regulatory (StAR) protein expression. Toxicology. 2003 May 3;187(2-3):139-48. doi: 10.1016/s0300-483x(03)00063-5.
• [206] Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
• [207] Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium. BMC Genomics. 2004 Aug 20;5(1):58. doi: 10.1186/1471-2164-5-58.
• [208] Identification and characterization of the human retinoid X receptor alpha gene promoter. Gene. 2006 May 10;372:118-27. doi: 10.1016/j.gene.2005.12.027. Epub 2006 Mar 6.
• [209] Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4.
• [210] Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 2009 Dec;100(12):2459-64.
• [211] Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30.
• [212] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [213] The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem. 2004 Nov 5;279(45):47298-310. doi: 10.1074/jbc.M404101200. Epub 2004 Aug 25.
• [214] Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
• [215] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [216] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [217] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [218] Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
• [219] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [220] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [221] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [222] The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem. 2004 Mar 5;279(10):8856-61. doi: 10.1074/jbc.M306422200. Epub 2003 Dec 18.
• [223] The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
• [224] Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011 Feb;53(2):548-57. doi: 10.1002/hep.24047. Epub 2010 Dec 10.
• [225] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [226] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [227] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [228] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [229] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [230] Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. doi: 10.1111/j.1365-2567.2007.02574.x. Epub 2007 Mar 7.
• [231] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [232] Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene. 2010 Sep 16;29(37):5159-70. doi: 10.1038/onc.2010.255. Epub 2010 Jun 21.
• [233] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [234] In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res. 2005 Apr;22(4):512-7. doi: 10.1007/s11095-005-2505-y. Epub 2005 Apr 7.
• [235] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [236] Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro. Int J Pharm. 2015 Nov 10;495(1):588-598. doi: 10.1016/j.ijpharm.2015.09.042. Epub 2015 Sep 21.
• [237] Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs. Eur J Pharm Biopharm. 2011 Feb;77(2):327-31. doi: 10.1016/j.ejpb.2010.12.009. Epub 2010 Dec 13.
• [238] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [239] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [240] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [241] Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
• [242] Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. Eur J Nutr. 2006 Mar;45(3):159-64. doi: 10.1007/s00394-005-0576-5. Epub 2005 Dec 20.
• [243] Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. J Toxicol Sci. 2015 Feb;40(1):127-36. doi: 10.2131/jts.40.127.
• [244] Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J Biol Chem. 2013 Jan 11;288(2):807-18. doi: 10.1074/jbc.M112.437970. Epub 2012 Dec 3.
• [245] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [246] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [247] Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
• [248] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [249] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [250] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [251] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [252] The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol In Vitro. 2001 Aug-Oct;15(4-5):399-405. doi: 10.1016/s0887-2333(01)00043-1.
• [253] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [254] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [255] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [256] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [257] Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro. 2009 Oct;23(7):1259-67.
• [258] Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
• [259] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [260] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [261] Functional characterization of peroxisome proliferator-activated receptor-/ expression in colon cancer. Mol Carcinog. 2011 Nov;50(11):884-900. doi: 10.1002/mc.20757. Epub 2011 Mar 11.
• [262] Aspirin-induced apoptosis in jurkat cells is not mediated by peroxisome proliferator-activated receptor delta. Mol Cell Biochem. 2004 Nov;266(1-2):57-63. doi: 10.1023/b:mcbi.0000049138.67699.7b.
• [263] (9)-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPAR induction: A possible evidence for the cancellation of PPAR/-mediated inhibition of PPAR in MDA-MB-231?cells. Arch Biochem Biophys. 2019 Feb 15;662:219-225. doi: 10.1016/j.abb.2018.12.011. Epub 2018 Dec 13.
• [264] Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Res. 2009 Sep;29(9):3647-58.
• [265] Use of transcriptomics in hazard identification and next generation risk assessment: A case study with clothianidin. Food Chem Toxicol. 2022 Aug;166:113212. doi: 10.1016/j.fct.2022.113212. Epub 2022 Jun 8.
• [266] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [267] Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
• [268] Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
• [269] Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
• [270] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [271] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [272] Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice. J Biol Chem. 2014 Aug 8;289(32):22437-49. doi: 10.1074/jbc.M114.548933. Epub 2014 Jul 1.
• [273] Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
• [274] Transcriptional Regulation of Human Arylamine N-Acetyltransferase 2 Gene by Glucose and Insulin in Liver Cancer Cell Lines. Toxicol Sci. 2022 Nov 23;190(2):158-172. doi: 10.1093/toxsci/kfac103.
• [275] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [276] The PPAR gamma agonist troglitazone induces musclin mRNA expression in human myotubes. Horm Metab Res. 2006 Sep;38(9):614-6. doi: 10.1055/s-2006-951310.
• [277] Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression. Biochim Biophys Acta. 2006 Mar-Apr;1759(3-4):141-51. doi: 10.1016/j.bbaexp.2006.04.005. Epub 2006 Apr 27.
• [278] Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan;5(1):95-108. doi: 10.1158/1541-7786.MCR-06-0125.
• [279] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [280] Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015 Jun 19;290(25):15799-15811. doi: 10.1074/jbc.M115.641167. Epub 2015 May 11.
• [281] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [282] Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines. Toxicol Appl Pharmacol. 2010 Nov 15;249(1):91-100.
• [283] Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
• [284] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [285] Activated thyroid hormone receptor modulates dioxin-inducible aryl hydrocarbon receptor-mediated CYP1A1 induction in human hepatocytes but not in human hepatocarcinoma HepG2 cells. Toxicol Lett. 2017 Jun 5;275:77-82.
• [286] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [287] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [288] Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
• [289] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [290] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [291] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [292] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [293] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [294] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [295] Detection of the mechanism of immunotoxicity of cyclosporine A in murine in vitro and in vivo models. Arch Toxicol. 2015 Dec;89(12):2325-37. doi: 10.1007/s00204-014-1365-9. Epub 2014 Sep 17.
• [296] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [297] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [298] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [299] Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
• [300] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [301] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.